Abstract
The increasing use of combination immune checkpoint Inhibitors (ICI) therapy increases the survival of metastatic cancer patients. However, it increases fatality due to uncommon fulminant complication of ICI cardiotoxicities which include ICI induced myocarditis (20-30% compared to 2-4% in general myocarditis), complete heart block (CHB), ventricular tachycardia, cardiac arrest, and cardiogenic shock.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
